<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103503</url>
  </required_header>
  <id_info>
    <org_study_id>Plexa Registry</org_study_id>
    <nct_id>NCT03103503</nct_id>
  </id_info>
  <brief_title>Plexa ICD Lead Registry</brief_title>
  <official_title>Plexa ICD Lead Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to confirm the long-term safety and reliability of
      BIOTRONIK's Plexa ICD lead.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall incidence of adverse events related to the Plexa lead from implant through 5 years.</measure>
    <time_frame>5 years post-implant</time_frame>
    <description>The purpose of primary endpoint 1 is to examine the overall incidence of adverse events related to the Plexa lead from implant through 5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of each individual type of AE that contributes to Primary Endpoint 1</measure>
    <time_frame>5 years post-implant</time_frame>
    <description>The purpose of secondary endpoint 1 is to examine the incidence of each individual type of adverse event that contributes to primary endpoint 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pacing threshold, sensing and impedance measurements for the Plexa lead through 5 years post-implant</measure>
    <time_frame>5 years post-implant</time_frame>
    <description>The purpose of secondary endpoint 2 is to examine the pacing threshold, sensing and impedance measurements for the Plexa lead through 5 years post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock impedance for the Plexa lead through 5 years post-implant</measure>
    <time_frame>5 years post-implant</time_frame>
    <description>The purpose of secondary endpoint 3 is to examine the shock impedance for the Plexa lead through 5 years post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates for protocol defined, Clinical Events Committee (CEC) adjudicated AEs excluded from primary safety endpoint 1, through 5 years post-implant</measure>
    <time_frame>5 years post-implant</time_frame>
    <description>The purpose of secondary endpoint 3 is to examine the adverse event rates for protocol defined, Clinical Events Committee (CEC) adjudicated AEs excluded from primary safety endpoint 1, through 5 years post-implant</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1271</enrollment>
  <condition>Implantable Defibrillator User</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The subject selected for participation should be from the investigator's general patient
        population according to the inclusion and exclusion criteria.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Successfully implanted with a BIOTRONIK ICD or CRT-D compatible system along with the
             Plexa lead no more than 30 days prior to consent

          -  Able to understand the nature of the registry and provide informed consent

          -  Available for follow-up visits on a regular basis at the study site for the expected
             5 years of follow-up

          -  Accepts BIOTRONIK Home MonitoringÂ® concept

          -  Age greater than or equal to 18 years

        Exclusion Criteria:

          -  Enrolled in any investigational cardiac device trial

          -  Enrolled in BIOTRONIK's QP ExCELs lead study

          -  Planned cardiac surgical procedures or interventional measures within the next 6
             months

          -  Expected to receive heart transplantation or ventricular assist device within 1 year

          -  Life expectancy of less than 1 year

          -  Patients reporting pregnancy at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karlene Cox</last_name>
    <phone>800-547-0394</phone>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>March 31, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
